Speaker
Description
The third most prevalent type of cancer in women is cervical cancer, which appears in the cervix. The cervix is the opening from the vagina into the womb. A cancerous tumour that develops from cervix cells may lead to cervical cancer. The precancerous condition known as dysplasia is the first sign of cervical cancer, which progresses quite slowly. Malignant tumour is a cancerous tumour capable of metastasis, or has the power to spread to healthy tissues in other parts of the body. Only females can develop cervical cancer. Most cervical cancers are related to human papilloma virus (HPV), a sexually transmitted infection. Various strains of HPV spread through sexual contact and are related to most cases of cervical cancer. The oncoproteins E6 and E7 of the Human Papillomavirus (HPV) are crucial for cervical cancers induced by viruses. Hence targeting these proteins is a must if we are to treat the disease. The newly synthesised imidazole compounds (1-7) have been found to have inhibitory activity against the E6 and E7 oncoproteins because they obstruct E6 and E7's capacity to bind to caspase 8 and E6AP, the proteins that facilitate the degradation of p53, in vitro. Additionally, both substances were able to raise the levels of p53 and caspase 8 in SiHa cervical cancer cells, which raised caspase 3 and 7 activity. Therefore, the imidazole compounds have been found to sensitized HPV+ cervical cells. This review provides a complete overview of the various studied carried using the imidazole containing compounds showing potent inhibitory action for Cervical cancer.